We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Proposes Metastasis-Free Survival Endpoint in Prostate Cancer Trials
FDA Proposes Metastasis-Free Survival Endpoint in Prostate Cancer Trials
The FDA Tuesday issued draft guidance for clinical trial sponsors of treatments for a rare form of prostate cancer — nonmestastatic, castration-resistant prostate cancer (nmCRPC) — and said it will consider metastasis-free survival as an endpoint.